GeoVax Labs (NASDAQ:GOVX) Earns Hold Rating from D. Boral Capital

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “hold” rating reiterated by investment analysts at D. Boral Capital in a note issued to investors on Thursday, Marketbeat Ratings reports.

Several other research analysts have also weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, GeoVax Labs has an average rating of “Hold” and an average target price of $187.50.

GeoVax Labs Stock Performance

Shares of GOVX opened at $1.53 on Thursday. GeoVax Labs has a 52 week low of $1.26 and a 52 week high of $47.13. The firm has a market capitalization of $2.78 million, a price-to-earnings ratio of -0.04 and a beta of 3.77. The business’s fifty day moving average price is $3.57 and its two-hundred day moving average price is $10.82.

Institutional Trading of GeoVax Labs

Large investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in GeoVax Labs in the fourth quarter valued at about $99,000. HRT Financial LP bought a new stake in GeoVax Labs in the fourth quarter valued at approximately $31,000. Renaissance Technologies LLC bought a new stake in shares of GeoVax Labs in the 4th quarter valued at $104,000. Hudson Bay Capital Management LP acquired a new stake in GeoVax Labs during the 3rd quarter worth about $47,000. Finally, Armistice Capital LLC acquired a new stake in GeoVax Labs during the third quarter worth approximately $253,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.